.Attribute Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) treatment of people with HER2+ state-of-the-art breast cancer cells as well as active or even dependable mind metastases presented consistent intracranial activity as well as wide spread efficacy of T-DXd.